{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Number of participants who were alive with evidence of complete or partial response, evaluated using RECIST 1.1 criteria. Patients that underwent rapid plasma genotyping and had an EGFR mutation and who were treated with erlotinib were included in this calculation.","groups":[{"description":"Erlotinib will be initially dosed at a pre-determine dosage daily, and it will be given on a 6-week cycle with treatment administered on an outpatient basis","id":"OG000","title":"EGFR Exon 19 Positive Treatment With Erlotinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"A total of 6 participants were treated with erlotinib on study.","reportingStatus":"POSTED","timeFrame":"From date of erlotinib initiation until the date of first documented disease progression or date of death from any cause, whichever came first. ORR was assessed up to 21 months after erlotinib initiation.","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}